Document Detail

Tiagabine: the safety landscape.
MedLine Citation:
PMID:  8595787     Owner:  NLM     Status:  MEDLINE    
Tiagabine (TGB) hydrochloride is a potential new antiepileptic drug (AED) undergoing clinical development. Experience in humans amounts to 1,810 patient-years of exposure. TGB was found to be tolerated in an integrated safety analysis of five double-blind, add-on therapy trials involving approximately 1,000 patients with epilepsy with difficult-to-control seizures with existing AEDs. Discontinuation resulting from adverse events were infrequent, occurring in 15% of patients receiving TGB compared to 5% receiving placebo. The most frequently reported adverse event was dizziness, which was usually transient and did not require medical intervention. Adverse events that were statistically significantly more common with TGB than placebo were dizziness, asthenia, nervousness, tremor, diarrhea, and depression (not major depression). Adverse events were usually mild to moderate in severity and transient, and most were associated with dose titration. The incidence, type, and severity of adverse events in long-term studies were comparable with those in short-term studies. Serious adverse events were uncommon and no idiosyncratic events were reported.
I E Leppik
Related Documents :
14698707 - Epilepsy surgery outcome among us veterans.
18041417 - Anxiety and depression in thai epileptic patients.
10996507 - Black-white differences in the psychosocial outcomes of epilepsy.
16247417 - Daclizumab for children with corticosteroid refractory graft-versus-host disease.
22114807 - Enhancing management of depression and type 1 diabetes in adolescents and young adults.
19664287 - The revised fibromyalgia impact questionnaire (fiqr): validation and psychometric prope...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Epilepsia     Volume:  36 Suppl 6     ISSN:  0013-9580     ISO Abbreviation:  Epilepsia     Publication Date:  1995  
Date Detail:
Created Date:  1996-04-17     Completed Date:  1996-04-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2983306R     Medline TA:  Epilepsia     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S10-S13     Citation Subset:  IM    
Department of Neurology, University of Minnesota, Minneapolis, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*,  therapeutic use
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Epilepsy / drug therapy*
Nipecotic Acids / adverse effects*,  therapeutic use*
Proportional Hazards Models
Treatment Outcome
gamma-Aminobutyric Acid / adverse effects*,  therapeutic use
Reg. No./Substance:
0/Anticonvulsants; 0/Nipecotic Acids; 0/Placebos; 115103-54-3/tiagabine; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Classification and reconstruction in revision acetabular arthroplasty with bone stock deficiency.
Next Document:  International experience with tiagabine add-on therapy.